Trial will test existing drugs against rare blood cancer
A clinical trial designed to test existing drugs in the treatment of a rare blood cancer has been launched at the Universities of Warwick and Birmingham.
Oct 27, 2020
0
6
A clinical trial designed to test existing drugs in the treatment of a rare blood cancer has been launched at the Universities of Warwick and Birmingham.
Oct 27, 2020
0
6
Myelodysplastic syndrome (MDS) is a bone marrow failure disorder characterized by intractable cytopenia and dysplastic hematological changes. MDS has a varied clinical course, with some patients remaining asymptomatic with ...
Oct 7, 2020
0
3
(HealthDay)—Iron chelation therapy (ICT) seems beneficial for iron-overloaded patients with low- or intermediate-1-risk myelodysplastic syndromes (MDS), according to a study published online March 24 in the Annals of Internal ...
Mar 24, 2020
0
1
In Spain, a workgroup of more than 400 researchers—the Spanish Group of Myelodysplastic Syndromes (GESMD)—meets twice a year to present projects and undertake collaborations that improve their work in the fight against ...
Nov 4, 2019
0
0
A research team from the Johns Hopkins Kimmel Cancer Center reports it has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes. ...
Oct 3, 2019
0
7
(HealthDay)—Transfusion dose density is an independent prognostic factor for progression-free survival (PFS) in patients with myelodysplastic syndromes treated with red blood cell transfusions (RBCTs), according to a study ...
Jun 24, 2019
0
1
(HealthDay)—For older patients undergoing allogeneic hematopoietic cell transplantation (alloHCT), a considerable part of total nonrelapse mortality (NRM) is attributable to population mortality, according to a study recently ...
Apr 3, 2019
0
1
Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis ...
Nov 30, 2018
0
2
It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents (ESA), which ...
Sep 24, 2018
0
0
(HealthDay)—Lenalidomide produces hematologic responses in myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) with ring sideroblasts (RS) and thrombocytosis (MDS/MPN-RS-T), although these responses are often ...
Nov 1, 2017
0
1